BioSpace News Archive

In this landmark study, a follow-up to BluePrint 1, a global team of thoracic pathologists reviewed the immunostains of five clinical grade PD-L1 IHC assays (22C3, 28-8, SP142, SP263, and 73-10).

CiToxLAB, a leading Contract Research Organization (CRO), announces the purchase of a new facility in Laval (Montreal, Canada) to meet the growing demand for bioanalysis and biomarkers services in support of preclinical and clinical programs, offering shorter lead times for development programs.

Antabio SAS announced today the completion of a 7.3M Euros series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard.

Ms. Fish was most recently the Chief Human Resources Officer for Marlin Equity Partners, a private equity firm.

Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.

Revance Therapeutics, today announced that the company will release third quarter 2017 financial results on Thursday, November 2, 2017 after the close of market.

Innoviva announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m. EDT/2:00 p.m. PDT to discuss the financial results and provide a corporate update.

Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of $125,000,000 of shares of its common stock.

Insulet is partnering with DexCom, Inc. (Dexcom) to provide the Omnipod System and a $200 gift card from Dexcom which can be used towards the purchase of a Dexcom G5 Mobile CGM (Continuous Glucose Monitoring) for qualified Animas insulin pump users.

Last month Maxogen Group successfully closed its current financing round.